A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). - Abstract - Europe PMC

IJMS, Free Full-Text

3D human nonalcoholic hepatic steatosis and fibrosis models

MASH CALL for Fast and Reliable Identification and Comparison of Drug Candidates - InSphero

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

2023-5892

3D In Vitro MASH Model for Preventive Screening

Firsocostat (MedChemExpress), Bioz

Role of Hepatic Stellate and Liver Sinusoidal Endothelial Cells in a Human Primary Cell Three-Dimensional Model of Nonalcoholic Steatohepatitis - ScienceDirect

Human‐based systems: Mechanistic NASH modelling just around the corner?

Multimodal NASH prognosis using 3D imaging flow cytometry and artificial intelligence to characterize liver cells